Cambridge Nutritional Sciences plc (LSE:CNSL), the AIM-quoted diagnostics company, reported a statutory loss before tax of £4.4 million for the year to 31 March 2026, against a profit the previous year. Most of that swing came from a single non-cash charge. The central question is how a £3.0 million Goodwill write-down and weaker trading combined to produce that loss, and what the rest of its results reveal about the underlying business.

A food sensitivity testing specialist

Cambridge Nutritional Sciences develops and sells tests that help practitioners and patients identify food sensitivities. Its largest product is FoodPrint, an IgG antibody food sensitivity test, alongside Food Detective, a rapid point-of-care test, and CNSLab, a UK laboratory testing service. CNSLab testing volumes rose 11% during the financial year. In March 2026 it launched GutDetective, a biomarker panel. The company sells into more than 60 countries, largely through distributors, and operates in India through its Omega DX (Asia) subsidiary.

The September 2026 final results

On 8 September 2026, the company reported Revenue of £7.0 million, down from £8.3 million. FoodPrint revenue fell 12% to £4.28 million and Food Detective dropped 46% to £0.97 million, while CNSLab rose 2% to £1.67 million. India grew 23% in sterling terms, but sales in the Americas fell 33% and Asia and the Far East declined 24%. Chair Carolyn Rand said: "While the global market threw its fair share of challenges our way, it also revealed the true resilience of our business."

One-off items totalled £3.27 million, of which £3.02 million was goodwill impairment, with smaller restructuring and legal costs. Before one-off items, the company made an operating loss of £1.21 million, against an operating profit of £0.40 million a year earlier, and adjusted EBITDA swung to a loss of £0.4 million from a profit of £0.4 million. The statutory loss after tax was £5.83 million, and net Assets fell to £5.68 million from £11.41 million. An Impairment of this kind generally reflects reduced expectations of future cash flows from the related assets, amid weaker regional trading.

Efficiency gains and cash

The results also showed operational improvements. Gross Margin rose to 67.8% from 65.3%, helped by Manufacturing yields increasing from about 52% to 65%. Chief executive James Cooper said: "The Business has found further improvements that have increased yields from 52.3% to 64.7%." Operating costs before one-off items fell 12% to £4.1 million, and a March 2026 restructure reduced UK headcount from 76 to 58 full-time equivalents. The company also took a £0.3 million bad Debt provision relating to Americas distributors. Board members also took a voluntary 10% salary reduction, and the company completed implementation of a new laboratory information management system.

Cash and deposits ended the year at £2.64 million, down from £4.87 million. Chief financial officer Ajay Patel said: "Cash balances remain sufficient for the Investment in the next few years." The board's Going Concern assessment runs to March 2028.

Risks and items to watch

The main risks are continued revenue decline in distributor markets, the cost of meeting the EU In Vitro Diagnostic Regulation, which the company expects to complete in 2027, and the pace of cash consumption. Its turnaround depends partly on a new global sales director, appointed in June 2026, converting the pipeline it says it built. The Annual General Meeting is scheduled for 28 October 2026. On 1 October 2026, a holding notification showed Spreadex's interest, including financial instruments, had fallen to about 11.2% of voting rights.

Conclusion

Cambridge Nutritional Sciences took a £3.0 million goodwill impairment in a year when revenue fell and key export markets weakened, driving a large statutory loss. Beneath that charge, its results show higher margins and lower costs, but a business that has yet to return to growth.